Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0893 placebo-controlled phase 2 study in adults with type 2 diabetes mellitus
2005-003869-17Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-0893 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoints: 24-hour weighted mean glucose and Safety and tolerability. Started Jul 2006; status: completed.
02
Drugs
MK-0893
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-003869-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003869-17.